Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Agenda for the Board of Danish Regions meeting in February 2025

On February 3, 2025, the Agenda for the Board of Danish Regions meeting was published. The meeting was held on February 6, 2025. Some of the themes discussed during the meeting are provided below.

Wellbeing economy: The wellbeing economy proposes using alternative measures beyond gross domestic product (GDP) for policy decisions, prioritizing public wellbeing and environmental sustainability. At the 2024 Regional Political Summit, it was proposed that Danish Regions work towards introducing the wellbeing economy as an actively used management tool in Denmark. The proposal was withdrawn, and instead, it was agreed to initiate a thematic discussion in the Board of Danish Regions.

Joint Letter from Danish Regions and the Danish Cancer Society to the Minister of the Interior and Health urging special measures to expand cancer treatment capacity in response to the rising patient numbers. The letter includes the proposal to extend emergency cancer funding into 2026 and an outline of the need for a strategic plan for capacity expansion toward 2040.

Status of the Common Regional Procurement Strategy 2020-2025, which aims to ensure efficient procurement, sustainability, and professionalization in the Danish healthcare sector:

  • Strategic areas include efficiency and supply security, sustainable (green) procurement, value-based procurement, professionalization, and data-driven procurement. For all areas, there has been significant development in the first four years of the Strategy period, and the regions have realized procurement savings despite prioritizing green procurement and a strong focus on security of supply;
  • With the Strategy, the regions have achieved 99% of the total savings target a year ahead of schedule;
  • During the strategy period, the regions increased their ambitions and cooperation in relation to green procurement with a view to supporting the implementation of the procurement track and the objectives of the Strategy regarding green hospitals. A joint regional group has been established to work on developing and supporting more green procurement; the regions are currently collaborating on the following areas: common Nordic packaging criteria, phase-out list for environmentally harmful substances, ecolabel policy, green supplier cooperation during the contract period, company-specific climate reduction requirements for production/raw materials. In addition to the concrete joint work with specific areas of focus, an important element is knowledge sharing and exchange of experiences regarding the green transition in the procurement area in the individual regions. The regions are also continuously working to disseminate green requirements in their tenders;
  • Since the adoption of the Strategy, the regions have also set a new ambitious goal to increase the number and share of joint procurement (excluding pharmaceuticals) so that they account for half of all procurement by 2029.

See the full details in Danish here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.